Stock Markets April 9, 2026 07:41 AM

Amazon to Distribute Lilly’s Oral Weight-Loss Pill Through Clinic Kiosks, Adds Same-Day Delivery

Amazon Pharmacy will stock Eli Lilly’s Foundayo at clinic kiosks and fulfill orders with same-day delivery where available, leveraging LillyDirect prescriptions

By Caleb Monroe LLY
Amazon to Distribute Lilly’s Oral Weight-Loss Pill Through Clinic Kiosks, Adds Same-Day Delivery
LLY

Amazon Pharmacy will make Eli Lilly’s newly approved oral weight-loss medication available at select kiosks inside its primary care clinics and offer same-day delivery to roughly half of U.S. customers, while continuing to fulfill prescriptions through LillyDirect and expand kiosk distribution beyond California over time.

Key Points

  • Amazon Pharmacy will stock Eli Lilly’s oral Foundayo weight-loss pill at select clinic kiosks and provide same-day delivery in areas where available.
  • Injectable GLP-1 drugs are not stocked in kiosks because they require refrigeration; oral pills do not and can be stored safely in kiosks, according to Amazon.
  • Amazon fulfills prescriptions through LillyDirect and has been stocking Novo Nordisk’s Wegovy pill in kiosks since January, with expansion plans beyond California tied to state regulations and provider partnerships.

Amazon said on Thursday that its pharmacy division will carry Eli Lilly’s newly approved oral weight-loss pill at dispensing kiosks located inside some of the company’s primary care clinics, and that it will offer same-day delivery of the medication in areas where that service is available.

Amazon Pharmacy first began delivering GLP-1 class medications in 2021. The company does not place injectable versions of these drugs in kiosks because those forms require refrigeration. "No need for cold storage is what allows for broader access and for them to be stored safely in a kiosk for dispensing," said Tanvi Patel, a vice president at Amazon Pharmacy.

Patel said about half of U.S. customers currently have access to same-day delivery and Amazon intends to expand that service. She added that all customers receive medications within four days under the pharmacy’s fulfillment approach.

Amazon Pharmacy will fill prescriptions made through Eli Lilly’s direct-to-consumer platform, LillyDirect, and has been stocking Novo Nordisk’s Wegovy pill at kiosks since January. Patel noted that Amazon benefits from Lilly’s early direct-to-consumer strategy, which positioned the Indianapolis-based drugmaker to work directly with dispensing partners.

Lilly recently announced it will sell its newly approved Foundayo weight-loss pill directly to cash-pay customers via LillyDirect at $149 per month for the lowest dose. Patel said customers can also access Amazon’s same-day delivery through Lilly’s prescribing partners, including WeightWatchers.

At present, Novo Nordisk’s rival Wegovy pill is available in five kiosks in California where customers can pick up medication at Amazon’s One Medical locations after a medical appointment. Amazon introduced kiosks last year to dispense commonly used medicines such as antibiotics, blood pressure drugs and asthma inhalers, saying the option reduces barriers to access and can limit shipping costs.

Patients who are not One Medical members can still schedule appointments and use the kiosks; an annual One Medical subscription is priced at $199 for one year. Patel said that as kiosks roll out beyond California, they may be placed in other providers’ clinics if state regulations permit.

Amazon has invested over $4 billion in 2025 toward an initiative to triple company-wide delivery options this year, with a focus on underserved small towns and rural communities. Patel said that by the end of 2026, Amazon expects same-day delivery access to reach 4,500 locales.


Context and commercial details

The move pairs Amazon’s growing pharmacy and primary care footprint with Lilly’s direct-to-consumer distribution for its oral GLP-1 product. By stocking a non-refrigerated pill in clinic kiosks and enabling same-day fulfillment where available, Amazon is extending an access point that bypasses cold-chain constraints associated with injectable treatments.

Risks

  • Regulatory limits on where kiosks can be placed may slow geographic expansion - impacts healthcare services and pharmacy distribution sectors.
  • Cold-chain requirements prevent injectable GLP-1 formulations from being dispensed via kiosks, limiting kiosk applicability to oral formulations - impacts pharmaceutical logistics and cold storage service providers.
  • Same-day delivery availability is currently limited to about half of U.S. customers and expansion timelines depend on infrastructure investments and regulatory approval - impacts e-commerce delivery and logistics sectors.

More from Stock Markets

Semiconductor Lead Times Climb Further Across Multiple Product Lines, Baird Says Apr 9, 2026 BofA Sees Momentum in U.S. Power & Utilities After Management Meetings; Buys Remain for Select Names Apr 9, 2026 Raymond James Sees Instacart Momentum After Cart Assistant Rollout Apr 9, 2026 Starbucks Appoints Former Chipotle Development Chief to Lead Coffeehouse Design and Growth Push Apr 9, 2026 Gulf Stocks Slip as Questions Grow Over Regional Truce Apr 9, 2026